South Eastern European Research Oncology Group

Quick facts

Phase 2 pipeline

• Capecitabine and Bevacizumab · Oncology
  Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• South Eastern European Research Oncology Group portfolio CI brief
• South Eastern European Research Oncology Group pipeline updates RSS

Related

• Sector hub: All tracked pharma companies